A Phase 1 Study of BGE-102, a Novel Oral NLRP3 Inhibitor, in Healthy Volunteers and Participants with Obesity and Elevated High-Sensitivity C-Reactive Protein

BGE-102 - BioAge Labs

https://cattendee.abstractsonline.com/meeting/21541/presentation/6894

Ling Chen, Aditi Deshpande, Taiz Salazar, Chris Patil, ann neale, Naisha Shah, Eric Morgen, Patrick Martin, Kevin Wilhelmsen, Kristen Fortney, paul rubin, BioAge Labs, Emeryville, CA

Sep 5, 2026